Focus on Haemostasis

The new version of the Quick Guide to Haemostasis is available!

The new version of the Quick Guide to Haemostasis is available!

The complete guide to haemostasis is back, in a completely updated and redesigned version. Alongside 11 in-depth chapters, it includes diagrams and tables to enhance understanding of haemostasis mechanisms. 

Published in English and regularly translated into other languages, this guide has proved an undeniable success with clinicians, pathologists and students alike. 

Read more
PiP edited collection Front cover

Collection of Pathology in Practice articles

Stago UK is delighted to reveal a collection of our recent features in Pathology in Practice (PiP). This collected edition covers a wide range of topics; from our ground-breaking new instrument, the sthemO 301, to the utility of our digital solutions in achieving UKAS accreditation. The complete list of the articles included in this anthology is:

Read more
Logo SightCall by Stago

Live video assistance available with our Hotline specialists

Helping you faster with our new live video call assistance! Stago has recently launched a new service to provide an enhanced experience for customers contacting the support line: a Visual Assistance Platform, powered by SightCall.

Read more
Quantra in ECMO monitoring

Quantra in ECMO monitoring - 12th November - Society for Clinical Perfusion Scientists AGM 2022

As part of Stago’s GOLD sponsorship, Dr Guillaume Hekimian from the Intensive Care Unit (ICU) of La Pitié-Salpêtrière Hospital, Paris will be giving a talk during the main programme of the Society for Clinical Perfusion Scientists ' AGM on Saturday 12th November titled “ECMO and Haemostasis: Why we need Point-of-Care Viscoelastic Testing and our Experience with Quantra” about his team’s experience with Quantra in ECMO.

Read more
Monitoring of factor VIII or IX levels in patients receiving extended half-life products

Monitoring of factor VIII or IX levels

Information letter to download: monitoring of factor VIII or IX levels in patients receiving extended half-life products.

Read more